查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999430

帶狀皰疹疫苗市場：按疫苗類型、劑量、年齡層、分銷管道和最終用戶分類的全球市場預測 – 2026-2032 年

Shingles Vaccine Market by Vaccine Type, Dosage, Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，帶狀皰疹疫苗市場價值將達到 20.2 億美元，到 2026 年將成長至 21.9 億美元，到 2032 年將達到 36.6 億美元，複合年成長率為 8.80%。

主要市場統計數據
基準年 2025 20.2億美元
預計年份：2026年 21.9億美元
預測年份：2032年 36.6億美元
複合年成長率 (%) 8.80%

全面概述影響帶狀皰疹疫苗策略的臨床、商業性和政策因素，以及這些因素對整個價值鏈相關人員的影響。

帶狀皰疹是由水痘-帶狀皰疹病毒重新運作引起的，由於其發病率老齡化成長而增加，且易引發嚴重的併發症，如帶狀皰疹後遺症神經痛，因此仍然是老年人群面臨的一項重大公共衛生問題。儘管疫苗技術的進步已經改變了預防策略，但支付方環境和分銷模式的變化正在影響疫苗的可及性和接種率。本執行摘要概述了正在重塑帶狀皰疹疫苗格局的最顯著的臨床、商業性和政策趨勢，並重點闡述了這些趨勢對研發、生產、分銷和患者照護等各個環節相關人員的影響。

對帶狀皰疹疫苗的引進和採購方法進行詳細說明，以及正在改變整個醫療保健生態系統中相關人員期望的多方面變革因素。

帶狀皰疹疫苗領域正經歷一系列變革，其影響​​範圍已超越產品性能，涵蓋分銷、支付方參與和患者期望等各個方面。包括改進的重組抗原平台和佐劑系統在內的技術進步，提高了疫苗的有效性標準並修訂了臨床指南，迫使醫療系統和臨床醫生重新評估成人免疫通訊協定。同時，低溫運輸物流和數位化分銷管道的進步正在擴大疫苗的可及性，同時也對庫存管理和供應商選擇提出了新的考量。

對關稅主導的貿易趨勢如何重塑帶狀皰疹疫苗的供應鏈決策、採購彈性策略和商業合約方法進行詳細分析。

關稅和貿易措施等政策的調整可能會對整個醫藥供應鏈產生連鎖反應，相關人員被敦促評估自身營運的韌性，以應對預計在2025年實施的關稅措施。製造商和經銷商正在重新審視其關鍵原料、佐劑和管瓶的籌資策略，以降低進口成本上升和海關延誤風險。為此，採購團隊正在努力實現供應商多元化，認證區域性製造商，並談判包含價格保護條款的長期契約，以確保供應的連續性。

策略洞察，闡明疫苗類型、年齡層、最終用戶、分銷管道和劑型如何相互作用並影響疫苗的引入和交付。

將帶狀皰疹疫苗市場細分，可以揭示產品、人口統計特徵、醫療機構、分銷模式和接種方法如何相互作用，從而影響疫苗的引入管道和服務提供模式。根據疫苗類型，此市場環境可分為重組帶狀皰疹疫苗和減毒活疫苗。重組疫苗在老年族群中已展現出較高的療效，並影響了臨床指引的製定；而減毒活病毒疫苗在特定臨床情況下仍然效用。決策者在評估產品系列，除了考慮影響下游物流的儲存和處理要求外，還必須考慮這些療效和安全性方面的差異。

跨區域比較觀點揭示了支付方趨勢、基礎設施和人口壓力如何推動世界各地不同的部署和存取策略。

區域趨勢正在影響帶狀皰疹疫苗價值鏈中相關人員的實際情況和策略挑戰。在美洲，公共和私人支付方越來越重視展現成人免疫接種計劃的價值，這加速了對社區推廣和綜合護理路徑的投資，旨在提高老年人的疫苗接種率。主要市場的醫療保健系統正在利用電子健康記錄和免疫接種登記系統來縮小醫療服務差距，而分銷網路則優先考慮冷藏物流和與連鎖藥局的合作，以最大限度地提高疫苗的可及性。

全面的競爭情報突顯了臨床證據、營運韌性和策略夥伴關係如何定義帶狀皰疹疫苗市場的領導地位。

如今，帶狀皰疹疫苗領域的競爭優勢不僅取決於臨床差異化，還取決於一系列綜合能力，包括供應鏈敏捷性、證據產生和多通路商業性營運能力。主要企業正在投資核准後研究和真實世界數據（REW）項目，以證明疫苗的長期療效，並為與保險公司和醫療系統進行合約談判提供支援。同時，低溫運輸物流、灌裝和包裝能力的卓越營運以及供應商多元化已成為降低關稅和貿易相關風險的策略重點。

透過協調證據產生、供應彈性、全通路分銷和相關人員合作，加速疫苗取得和接種率的實用建議。

業界領導者應優先採取一系列切實可行且影響深遠的措施，以應對帶狀皰疹疫苗領域瞬息萬變的局面，並掌握新興機會。首先，各機構需要投資產生細緻的真實世界數據（REW），以展現不同年齡層和臨床亞組的疫苗療效對比，從而在與支付方談判以及與臨床醫生探討疫苗採納問題時，提出更具提案的價值主張。其次，他們可以透過供應商多元化、建立區域製造夥伴關係關係以及檢驗的低溫運輸緊急應變計劃來增強供應鏈韌性，從而降低貿易和關稅波動帶來的風險。

我們採用透明的混合方法研究途徑，結合專家訪談、監管資訊和情境分析，為決策者提供可操作的、檢驗的見解。

本分析基於混合調查方法，旨在整合關鍵相關人員的見解，並結合嚴謹的二手研究資料進行整合和檢驗。核心調查方法結合了對臨床專家、採購經理和分銷合作夥伴的深入訪談，以及從公開的監管公告、臨床文獻和政策聲明中資料提取。訪談在不同的醫療機構和地區進行，旨在了解影響疫苗供應的運作差異，並全面檢驗有關疫苗部署障礙和促進因素的新主題。

我們將透過簡潔地整合與臨床進展、供應韌性、細微的細分差異和區域差異相關的策略挑戰，來實現疫苗取得目標。

總之，帶狀皰疹疫苗市場正處於轉折點，技術進步、人口結構變化和採購模式的演變相互交織，為整個價值鏈上的相關人員帶來了挑戰和機會。重組疫苗平台和改進的物流解決方案提高了人們對臨床療效的期望，並拓展了更廣泛的成人免疫策略的可能性；同時，關稅和貿易趨勢要求供應鏈結構更具韌性，商業模式更具適應性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：帶狀皰疹疫苗市場：依疫苗類型分類

  • 重組疫苗
  • 減毒活病毒疫苗

第9章：帶狀皰疹疫苗市場：依劑量分類

  • 多次給藥
  • 單一劑量

第10章：帶狀皰疹疫苗市場：依年齡層別分類

  • 50-59歲
  • 60-69歲
  • 70歲以上

第11章：帶狀皰疹疫苗市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
    • 數位藥房
    • 電子商務平台
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第12章：帶狀皰疹疫苗市場：依最終用戶分類

  • 診所
    • 當地診所
    • 私人診所
  • 醫院
    • 綜合醫院
    • 專科醫院

第13章：帶狀皰疹疫苗市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：帶狀皰疹疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：帶狀皰疹疫苗市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國帶狀皰疹疫苗市場

第17章：中國帶狀皰疹疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AIM Vaccine Co., Ltd.
  • Bavarian Nordic A/S
  • Beijing Institute of Biological Products Co., Ltd.
  • Bharat BIoTech International Limited
  • Biological E. Limited
  • CanSino Biologics Inc.
  • CanSinoBIO
  • Changchun BCHT BIoTechnology Co., Ltd.
  • Chengdu Institute of Biological Products Co., Ltd.
  • Daiichi Sankyo Company, Limited
  • Dynavax Technologies Corporation
  • GeneOne Life Science
  • GlaxoSmithKline plc
  • Green Cross Corporation
  • Jiangsu Recbio Technology Co., Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Life Sciences Co., Ltd.
  • SK chemicals
  • Vaccitech plc
  • Valneva SE
  • Vaxart, Inc.
  • Yuxi Walvax BIoTechnology Co., Ltd.
Product Code: MRR-563BF1FCEEC2

The Shingles Vaccine Market was valued at USD 2.02 billion in 2025 and is projected to grow to USD 2.19 billion in 2026, with a CAGR of 8.80%, reaching USD 3.66 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.02 billion
Estimated Year [2026] USD 2.19 billion
Forecast Year [2032] USD 3.66 billion
CAGR (%) 8.80%

Comprehensive orientation to the clinical, commercial, and policy forces shaping shingles vaccine strategy with implications for stakeholders across the value chain

Shingles, caused by reactivation of varicella-zoster virus, remains a significant public health concern for older adults due to rising incidence with advancing age and the debilitating complications associated with postherpetic neuralgia. Advances in vaccine technology have reshaped prevention strategies, while evolving payer landscapes and distribution shifts are influencing access and uptake. This executive summary consolidates the most salient clinical, commercial, and policy trends that are reshaping the shingles vaccine environment and highlights the implications for stakeholders across development, manufacturing, distribution, and patient care delivery.

In recent years, recombinant vaccine platforms have introduced higher-efficacy alternatives to older live-attenuated formulations, altering clinical recommendations and immunization pathways. At the same time, demographic pressures from aging populations and intensified focus on adult immunization programs are generating renewed attention among public health authorities and private payers. As a result, manufacturers, providers, and distributors are reassessing supply strategies, service delivery models, and communication approaches to maximize coverage and minimize preventable disease burden.

This introduction frames the report's subsequent analysis, which explores transformative shifts in the landscape, cumulative policy impacts, segmentation-driven demand drivers, regional nuances, competitive positioning, recommended actions for industry leaders, and the research methodology underpinning the findings. The intent is to present a coherent, decision-oriented narrative that supports strategic planning and operational execution in an increasingly complex environment.

Detailed exposition of the multi-dimensional disruptive forces altering shingles vaccine adoption, procurement approaches, and stakeholder expectations across health ecosystems

The shingles vaccine landscape is experiencing a set of transformative shifts that extend beyond product performance and into distribution, payer engagement, and patient expectations. Technological advances, including improved recombinant antigen platforms and adjuvant systems, have elevated efficacy benchmarks and altered clinical guidance, prompting health systems and clinicians to reevaluate adult immunization protocols. Concurrently, advances in cold-chain logistics and digital distribution channels are enabling broader access while introducing new considerations for inventory management and supplier selection.

Payer dynamics are shifting toward value-based procurement and performance-linked contracting, which is incentivizing manufacturers to demonstrate long-term clinical and economic benefits. This emphasis on outcome-oriented reimbursement is driving increased investment in real-world evidence generation and post-marketing surveillance. In parallel, regulatory authorities are refining approval and labeling pathways to better reflect age-stratified risk-benefit profiles, which in turn affects recommendations from national immunization technical advisory groups and clinical societies.

Patient expectations and provider workflows are also evolving. Older adults are increasingly informed about vaccine options and seek clear guidance on comparative efficacy and safety, while primary care settings and specialist clinics are integrating vaccination into routine chronic disease management visits. Finally, the growing role of digital pharmacies and e-commerce platforms in medication access is accelerating the adoption of novel distribution models, necessitating new governance around cold-chain assurance and adherence support. Together, these shifts are redefining competitive advantage and operational priorities across the ecosystem.

In-depth analysis of how tariff-driven trade dynamics are reshaping supply chain decisions, procurement resilience strategies, and commercial contracting approaches for shingles vaccines

Policy adjustments such as tariffs and trade measures can create downstream effects across pharmaceutical supply chains, and anticipated tariff actions in the United States in 2025 have prompted stakeholders to assess operational resiliency. Manufacturers and distributors are re-evaluating sourcing strategies for critical raw materials, adjuvants, and vials to mitigate exposure to increased import costs and potential customs-related delays. In response, procurement teams are diversifying supplier bases, accelerating qualification of regional manufacturers, and negotiating longer-term contracts with price protection clauses to preserve continuity of supply.

Logistics partners and cold-chain providers are also adapting to potential cost shifts by optimizing routing, consolidating shipments, and exploring nearshoring opportunities to reduce tariff-related risk. These operational adjustments may increase lead times for certain inputs while prompting investment in domestic fill-and-finish capacity and additional cold-storage infrastructure. Clinicians and health systems should expect potential variations in procurement cadence as supply planners prioritize allocations based on contractual commitments and anticipated demand.

From a commercial perspective, increased import duties can pressure pricing strategies, margin structures, and contracting approaches with payers and distributors. Manufacturers may pursue differentiated pricing across channels or seek to bundle services-such as adherence support or analytics-to sustain overall value propositions. Regulatory and policy stakeholders are likely to intensify collaboration to expedite approvals for alternative suppliers and to ensure that national immunization efforts remain resilient in the face of trade-driven disruptions. Overall, the cumulative effect underscores the importance of proactive supply chain governance, scenario-based planning, and strengthened public-private coordination.

Strategic segmentation-driven insights that decode how vaccine type, age cohorts, end users, distribution channels, and dosing formats interact to influence adoption and delivery

Segmentation of the shingles vaccine landscape illuminates how product, demographic, care setting, distribution patterns, and dosing regimens interact to shape adoption pathways and service delivery models. Based on vaccine type, the environment distinguishes between recombinant zoster vaccine formulations, which have influenced clinical guidelines through higher observed efficacy in older cohorts, and live-attenuated zoster vaccine options that retain relevance in specific clinical circumstances. Decision-makers evaluating product portfolios must consider these efficacy and safety differentials alongside storage and handling requirements that affect downstream logistics.

Based on age group, demand drivers and clinical priorities vary across those aged 50 to 59 years, 60 to 69 years, and those 70 years and above. Younger older adults often present opportunities for proactive preventive outreach and workplace-based vaccination programs, whereas patients aged 70 and above frequently require tailored messaging around comorbidity management and safety signals. Providers must therefore align clinical communications and outreach workflows to the age-stratified risk-benefit calculus in order to improve uptake across cohorts.

Based on end user, delivery pathways bifurcate between clinics and hospitals, with clinics further differentiated into community clinics and private clinics and hospitals further categorized into general hospitals and specialty hospitals. Community clinics often serve as primary access points for preventive care with strong ties to local public health initiatives, while private clinics frequently emphasize patient convenience and bundled preventive services. General hospitals manage large-scale procurement and account for inpatient vaccination needs, whereas specialty hospitals may target vaccination for high-risk patient populations undergoing specific therapies. Each end-user segment requires distinct engagement strategies related to inventory management, clinician education, and reimbursement navigation.

Based on distribution channel, access is facilitated through hospital pharmacies, online pharmacies, and retail pharmacies, with online pharmacies further consisting of digital pharmacies and e-commerce platforms and retail pharmacies including chain pharmacies and independent pharmacies. Hospital pharmacies play a central role in institutional procurement and cold-chain stewardship, while online channels enable convenience and direct-to-consumer fulfillment that must be supported by robust temperature control and authentication protocols. Chain retail pharmacies offer scale and standardized vaccination services, whereas independent pharmacies provide localized patient counseling and flexible scheduling. Channel strategies must therefore integrate service design, cold-chain verification, and digital engagement to ensure both accessibility and adherence.

Based on dosage, delivery considerations span multi-dose and single-dose presentations. Multi-dose presentations can improve supply efficiency in high-volume settings but require stringent cold-chain and multi-dose vial handling procedures, whereas single-dose presentations support point-of-care convenience and reduce wastage in lower-volume environments. Manufacturers and providers should weigh dosing format decisions against clinic throughput, storage constraints, and patient flow dynamics to optimize both clinical outcomes and operational performance.

Comparative regional perspectives that reveal how payer dynamics, infrastructure, and demographic pressures drive differentiated adoption and access strategies across global theaters

Regional dynamics shape both the operational realities and strategic imperatives for stakeholders across the shingles vaccine value chain. In the Americas, public and private payers are increasingly focused on adult immunization schedules and value demonstration, which has accelerated investments in community outreach and integrated care pathways to improve coverage among older adults. Health systems in major markets are leveraging electronic health records and immunization registries to close care gaps, while distribution networks emphasize refrigerated logistics and chain pharmacy partnerships to maximize access.

In Europe, Middle East & Africa, regulatory heterogeneity and variable health system maturity produce a mosaic of adoption scenarios. High-income countries within the region generally align their clinical guidance with emerging efficacy evidence, while middle- and lower-income countries prioritize cost-effective procurement and targeted risk-group immunization. Cold-chain infrastructure variability in certain markets underscores the importance of adaptable product formats and decentralized storage solutions. Cross-border procurement mechanisms and regional regulatory harmonization efforts are increasingly relevant for manufacturers considering supply commitments and pricing strategies.

In the Asia-Pacific region, demographic shifts and expanding healthcare infrastructure are driving heightened demand for adult immunization services. Many markets are scaling up primary care capability and digital health platforms that can facilitate vaccine awareness and appointment scheduling. Local manufacturing capacity and strategic partnerships are likewise being prioritized to enhance supply security and shorten lead times. Across these regional contexts, tailored commercialization models that account for payer structure, distribution maturity, and public health priorities will be essential to achieving sustainable adoption and programmatic impact.

Holistic competitive intelligence highlighting how clinical evidence, operational resilience, and strategic partnerships define leadership in the shingles vaccine landscape

Competitive positioning in the shingles vaccine arena now rests on an integrated set of capabilities that extend beyond clinical differentiation to include supply chain agility, evidence generation, and multi-channel commercial excellence. Leading organizations are investing in post-authorization studies and real-world evidence programs to substantiate long-term effectiveness and to support contracting discussions with payers and health systems. At the same time, operational excellence in cold-chain logistics, fill-and-finish capacity, and supplier diversification has become a strategic priority to mitigate tariff and trade-related risks.

Strategic alliances and manufacturing partnerships are increasingly common as companies seek to broaden geographic reach while containing capital expenditure. Collaborative approaches to distribution-combining hospital procurement networks with retail pharmacy programs and digital fulfillment-are enabling more seamless patient journeys. Marketing efforts are focusing on clear, age-tailored clinical messaging and on clinician-facing education to ensure that vaccine options are integrated into routine care for older adults. Additionally, firms that develop robust adherence and patient-support services are better positioned to demonstrate value to payers and providers under outcome-oriented contracting models.

Intellectual property stewardship, regulatory preparedness, and the capacity to scale commercial operations rapidly during periods of heightened demand further distinguish market leaders. Organizations that align clinical evidence, operational resilience, and stakeholder engagement are most likely to sustain competitive advantage in a dynamic landscape where product efficacy, distribution integrity, and payer alignment converge to determine adoption outcomes.

Action-oriented recommendations that align evidence generation, supply resilience, omnichannel distribution, and stakeholder collaboration to accelerate vaccine access and uptake

Industry leaders should prioritize a set of pragmatic, high-impact actions to navigate the evolving shingles vaccine environment and to capitalize on emerging opportunities. First, organizations must invest in granular real-world evidence generation that demonstrates comparative effectiveness across age bands and clinical subgroups, enabling more compelling value propositions in payer negotiations and clinician adoption discussions. Second, strengthening supply chain resilience through supplier diversification, regional manufacturing partnerships, and validated cold-chain contingency plans will reduce exposure to trade and tariff volatility.

Third, manufacturers and distributors should advance omnichannel distribution strategies that harmonize hospital procurement, retail pharmacy scale, and secure online fulfillment, while ensuring rigorous cold-chain verification and patient adherence support. Fourth, tailored engagement programs for different end users-community clinics, private clinics, general hospitals, and specialty hospitals-will improve uptake by aligning service delivery models and inventory management to specific operational needs. Fifth, commercial teams should develop flexible contracting frameworks and bundled service offerings that reflect payer preferences for outcomes and long-term value, thereby facilitating access in both public and private settings.

Finally, cross-sector collaboration with public health authorities, patient advocacy groups, and clinical societies will amplify outreach efforts and establish clearer adult immunization pathways. By combining evidence generation, operational readiness, channel optimization, and stakeholder alignment, industry leaders can enhance vaccine accessibility and deliver measurable public health impact.

Transparent mixed-methods research approach that integrates expert interviews, regulatory synthesis, and scenario analysis to produce actionable, validated insights for decision-makers

This analysis draws on a mixed-methods research approach designed to integrate primary stakeholder insights with rigorous secondary synthesis and validation. The core methodology combined in-depth interviews with clinical experts, procurement leaders, and distribution partners alongside structured data extraction from public regulatory communications, clinical literature, and policy statements. Interviews were conducted across a range of care settings and regions to capture the operational diversity influencing vaccine delivery and to triangulate emerging themes around adoption barriers and enablers.

Complementing qualitative insights, the research incorporated scenario-based supply chain analysis to assess resilience considerations under different trade and policy conditions. Key assumptions were tested through sensitivity checks and cross-validated with logistics and manufacturing specialists to ensure feasibility and practical relevance. The approach prioritized transparency of sources, explicit documentation of analytic steps, and iterative validation with subject-matter experts to reduce bias and increase applicability for decision-makers.

Ethical considerations were observed in all primary research activities, and data handling adhered to relevant confidentiality and privacy standards. Where applicable, clinical findings referenced peer-reviewed evidence and regulatory guidance to contextualize recommendations. The resulting synthesis emphasizes actionable intelligence and pragmatic pathways for implementation, intended to inform strategic planning rather than provide normative policy prescriptions.

Concise synthesis of strategic imperatives linking clinical advancement, supply resilience, segmentation nuance, and regional variation to operationalize vaccine access goals

In conclusion, the shingles vaccine landscape is at an inflection point where technological advances, demographic shifts, and evolving procurement paradigms intersect to create both challenges and opportunities for stakeholders across the value chain. Recombinant vaccine platforms and improved logistics solutions are raising clinical performance expectations and expanding the scope for broader adult immunization strategies, while tariff and trade dynamics demand more resilient supply chain architectures and adaptive commercial models.

Segmentation nuances across vaccine type, age cohorts, care settings, distribution channels, and dosing formats underscore the importance of tailored approaches that align product attributes with real-world delivery constraints. Regional differences further emphasize the need for customizable engagement models that consider payer structures, infrastructure maturity, and local clinical priorities. Competitive advantage will accrue to organizations that can combine robust evidence generation with operational excellence and flexible contracting to meet the needs of payers, providers, and patients.

Ultimately, proactive planning, strategic collaboration, and investment in both clinical and logistical capabilities will determine which stakeholders are best positioned to improve access and deliver measurable public health impact. This report is intended as a decision-oriented resource to guide such investments and to support evidence-based action across the shingles vaccine ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Shingles Vaccine Market, by Vaccine Type

  • 8.1. Recombinant Zoster Vaccine
  • 8.2. Zoster Vaccine Live

9. Shingles Vaccine Market, by Dosage

  • 9.1. Multi Dose
  • 9.2. Single Dose

10. Shingles Vaccine Market, by Age Group

  • 10.1. 50 To 59 Years
  • 10.2. 60 To 69 Years
  • 10.3. 70 Years And Above

11. Shingles Vaccine Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
    • 11.2.1. Digital Pharmacies
    • 11.2.2. E-commerce Platforms
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Shingles Vaccine Market, by End User

  • 12.1. Clinics
    • 12.1.1. Community Clinics
    • 12.1.2. Private Clinics
  • 12.2. Hospitals
    • 12.2.1. General Hospitals
    • 12.2.2. Specialty Hospitals

13. Shingles Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Shingles Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Shingles Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Shingles Vaccine Market

17. China Shingles Vaccine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AIM Vaccine Co., Ltd.
  • 18.6. Bavarian Nordic A/S
  • 18.7. Beijing Institute of Biological Products Co., Ltd.
  • 18.8. Bharat Biotech International Limited
  • 18.9. Biological E. Limited
  • 18.10. CanSino Biologics Inc.
  • 18.11. CanSinoBIO
  • 18.12. Changchun BCHT Biotechnology Co., Ltd.
  • 18.13. Chengdu Institute of Biological Products Co., Ltd.
  • 18.14. Daiichi Sankyo Company, Limited
  • 18.15. Dynavax Technologies Corporation
  • 18.16. GeneOne Life Science
  • 18.17. GlaxoSmithKline plc
  • 18.18. Green Cross Corporation
  • 18.19. Jiangsu Recbio Technology Co., Ltd.
  • 18.20. Johnson & Johnson
  • 18.21. Merck & Co., Inc.
  • 18.22. Moderna, Inc.
  • 18.23. Serum Institute of India Pvt. Ltd.
  • 18.24. Sinovac Life Sciences Co., Ltd.
  • 18.25. SK chemicals
  • 18.26. Vaccitech plc
  • 18.27. Valneva SE
  • 18.28. Vaxart, Inc.
  • 18.29. Yuxi Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. GCC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GCC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 169. GCC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 170. GCC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. G7 SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. G7 SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 199. G7 SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. G7 SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. G7 SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. G7 SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. NATO SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. NATO SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. NATO SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 210. NATO SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. NATO SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. NATO SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)